Please login to the form below

Not currently logged in
Email:
Password:

PhRMA appoints new EVP of public affairs

The Pharmaceutical Research and Manufacturers of America has appointed Josephine Martin as executive vice president, public affairs
The Pharmaceutical Research and Manufacturers of America (PhRMA) has appointed Josephine Martin as executive vice president, public affairs, reporting to PhRMA president and CEO John J Castellani, with effect from March 1, 2011. 

Martin, former senior vice president of public affairs at Ketchum, will be responsible for leading and managing PhRMA's communications and alliance development functions. 

Before joining Ketchum, Martin held leading public affairs positions at Golin Harris and National Media, Inc. Her health policy communications experience was developed earlier in her career as senior vice president, public affairs for the Federation of American Hospitals, and vice president of communications at the American Red Cross.

"We are thrilled to have Josie join our team at PhRMA. She brings extensive and successful experience in DC public affairs – with a particular strength in health policy communications," Castellani said. 

Commenting on her appointment, Martin said: "There are few, if any, American industries that positively impact people's lives in so many ways -- from improving health and productivity to providing good jobs, to strengthening local and national economies – as the biopharmaceutical sector." 

"I am excited to join such an energised, impactful organisation as PhRMA, and I relish the chance to bring my experience to bear as we work to best convey the tremendous value of this innovative sector," she continued.

7th February 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics